Teva in Poland announced the donation of two drugs that are being monitored by the international medical community in terms of the effectiveness of treating COVID-19 infections around the world: azithromycin and hydroxychloroquine.
Press Release
The donation concerns 5000 packages of a drug containing the active substance azithromycin and 270 packages of a drug containing the active substance hydroxychloroquine, which will be placed at the disposal of the Central Database of Sanitary and Anti-Epidemic Reserves for Polish hospitals.
Both of these drugs are currently under intensive research aimed at confirming previous individual observations that give hope for efficacy in the treatment of COVID-19 infection (hydroxychloroquine) and in the treatment of concomitant bacterial infections (azithromycin).
At the same time, they begin to appear in the recommendations issued by Medical Societies, paying special attention, however, to the fact that the therapy should take place only under the supervision of a physician.
Teva is active in the fight against the pandemic. We fulfill our mission towards patients and society as a partner for the health care system in Poland. Our factories around the world, including our factory in Krakow, constantly produce drugs, also in times of epidemics, thanks to the daily dedication of our employees.
Thanks to the global reach of our activity, we increase access to therapeutic solutions for Polish patients and provide Polish doctors with two drugs whose effectiveness in the treatment of COVID-19 infections is currently subject to global observations and raises the hopes of the medical world – says Michał Nitka, CEO of Teva Pharmaceuticals of the region Central and Eastern Europe.
Teva’s dozen factories around the world are constantly working with consistent intensity to supply and provide essential drugs to millions of patients every day. In addition, Teva is actively reviewing a wide range of medicinal products to determine if the company can increase its supply of drugs that may be useful in meeting the enormous and urgent needs associated with the COVID-19 health crisis.
Press Release